Brokerage firm Jefferies Maintains its rating on Alnylam Pharmaceuticals(NASDAQ:ALNY). In a research note issued to the investors, the brokerage major Raises the price-target to $86.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Aug 5, 2016.
In a different note, Morgan Stanley said it Initiates Coverage on Alnylam Pharmaceuticals, according to a research note issued on Aug 2, 2016. The shares have been rated ‘Overweight’ by the firm.
Alnylam Pharmaceuticals (ALNY) shares turned negative on Wednesdays trading session with the shares closing down -0.48 points or -0.65% at a volume of 3,39,536. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $73.53. The peak price level was also seen at $73.53 while the days lowest was $72. Finally the shares closed at $73.1. The 52-week high of the shares is $116.96 while the 52-week low is $49.96. According to the latest information available, the market cap of the company is $6,266 M.
Alnylam Pharmaceuticals(ALNY) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $8.71M. Analysts had an estimated revenue of $8.09M. Earnings per share were $-1.05. Analysts had estimated an EPS of $-1.24.
Several Insider Transactions has been reported to the SEC. On Apr 21, 2016, John Maraganore (Chief Executive Officer) sold 30,151 shares at $67.87 per share price.Also, On Mar 10, 2016, Michael W Bonney (director) purchased 2,000 shares at $58.36 per share price.On Feb 3, 2016, Sanofi (10% owner) purchased 205,030 shares at $69.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.